Advisory & Diligence for Med-Tech, Radiology AI, and Advanced Materials

    Operator-grade analysis through a clinical lens. Clear risks. Clear next steps. No fluff.

    We provide research and product guidance—not medical, legal, or financial advice.

    What you get

    • Evidence-first review of claims and clinical feasibility
    • Workflow fit analysis — what clinicians will actually use
    • Regulatory and reimbursement constraints — what breaks adoption
    • Competitive landscape and differentiation — what's defensible
    • Clear risk register + what would change the conclusion

    Three ways to work with us

    Evidence & Risk Memo

    Best for: founders, investors, and teams who need clarity fast

    • Evidence synthesis with citations
    • Adoption / workflow fit assessment
    • Regulatory + reimbursement constraints
    • Competitive snapshot
    • Key risks + failure modes

    Turnaround: typically 3–10 days (depending on scope)

    Request a memo quote

    Clinical Product Spec Sprint

    Best for: practices and teams that want a workflow tool built

    • 60–90 min intake call
    • Requirements + workflow mapping
    • Feature set + prioritized roadmap
    • Integration needs (none / SSO / EHR)
    • Build plan + timeline + budget range
    Request a build scope

    Advisory (Selective)

    Best for: high-stakes projects where ongoing input changes the outcome

    • Roadmap and positioning for clinician adoption
    • Demo and pitch refinement for hospitals / investors
    • Ongoing design and workflow feedback

    Reserved for teams with active execution and clear deliverables.

    Submit request

    Focus areas

    Med-Tech diligence

    Clinical feasibility, user fit, and adoption risks for devices in IR/OR/procedural medicine.

    Radiology & procedural AI

    Where AI adds real utility vs. where it creates risk, liability, or workflow drag.

    Graphene & advanced materials

    Commercialization pathways, realistic use cases, and partner strategy.

    Licensing strategy

    Defensibility of IP, partner shortlist, outreach structure, and deal pathway clarity. Coordinated with qualified partners as needed.

    When needed, we connect teams with specialized validation partners (e.g., biocompatibility testing and relevant labs) to accelerate credible proof.

    Who this is for

    • Founders building clinician-facing products
    • Teams preparing for pilots, demos, or fundraising
    • Investors who want a clinical reality check before allocating capital
    • Practices exploring workflow tools for documentation, coding, or prior auth

    Start here

    Pick the path that matches your need. If you're unsure, choose "Memo" for analysis or "Build" for software.

    Frequently asked questions

    Do you provide financial advice?

    No. We provide research, analysis, and product guidance. We do not provide investment, financial, legal, or medical advice. See our Terms of Service for details.

    Do you need access to patient data?

    No. Do not submit Protected Health Information (PHI). Our analysis is based on published evidence, clinical workflows, and product specifications — not patient records.

    Do you integrate with hospital systems?

    Custom builds can include integration planning (SSO, EHR, PACS). Start with a Spec Sprint to map requirements and identify the right integration pathway.

    What's the difference between a Memo and a Spec Sprint?

    A Memo is a written analysis — evidence, risks, competitive landscape. A Spec Sprint is a discovery process for building software — requirements, features, roadmap, and budget. Choose Memo for diligence, Sprint for product planning.

    How do I know which option to pick?

    If you need to understand risk before making a decision, start with a Memo. If you need a tool built for your practice or team, start with a Spec Sprint. If neither fits, submit a general request and we'll point you in the right direction.

    Written and reviewed by Pouyan Golshani, MD, Interventional Radiologist — Last updated August 27, 2025